v3.26.3
Document and Entity Information - USD ($)
12 Months Ended
Sep. 30, 2026
Nov. 06, 2026
Mar. 31, 2026
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Sep. 30, 2026    
Document Fiscal Year Focus 2026    
Document Fiscal Period Focus FY    
Trading Symbol ENTA    
Entity Registrant Name ENANTA PHARMACEUTICALS, INC    
Entity Central Index Key 0001177648    
Current Fiscal Year End Date --09-30    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Common Stock, Shares Outstanding   29,158,815  
Entity Public Float     $ 264,303,817
Title of 12(b) Security Common Stock, par value $0.01 per share    
Security Exchange Name NASDAQ    
Entity File Number 001-35839    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-3205099    
Entity Address, Address Line One 4 Kingsbury Avenue    
Entity Address, City or Town Watertown    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02472    
City Area Code 617    
Local Phone Number 607-0800    
Document Annual Report true    
Document Transition Report false    
Documents Incorporated by Reference Information for Part III of this Form 10-K will either (i) be incorporated by reference to portions of the registrant’s Definitive Proxy Statement for its 2027 Annual Meeting of Stockholders, or (ii) if the Definitive Proxy is not filed with the Securities and Exchange Commission within 120 days after the registrant’s fiscal year end of September 30, 2026, it will be provided by amendment to this Form 10-K.    
Auditor Name PricewaterhouseCoopers LLP    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 238    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Enanta Pharmaceuticals, Inc. and its subsidiary (the "Company") as of September 30, 2026 and 2025, and the related consolidated statements of operations, of comprehensive loss, of stockholders’ equity and of cash flows for each of the three years in the period ended September 30, 2026, including the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2026 and 2025, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2026 in conformity with accounting principles generally accepted in the United States of America.